Aptevo (APVO) CFO Daphne Taylor Converts 638 RSUs to Shares

What Happened

• Daphne Taylor, SVP and Chief Financial Officer of Aptevo Therapeutics (APVO), reported the conversion of 638 restricted stock units (RSUs) into 638 shares on August 6, 2026. The filing also shows 638 shares disposed at $0.00 (no cash proceeds) in connection with the same conversion.
• No cash value is reported for the disposal; the transaction reflects a conversion of equity awards rather than an open‑market sale or purchase.

Key Details

• Transaction date: August 6, 2026. Filing date: August 10, 2026 (filed within the usual two-business-day window).
• Transaction type: Conversion/exercise of derivative (Form 4 code M) — 638 shares acquired and 638 shares disposed, disposal price reported as $0.00.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — RSUs convert one‑for‑one into common stock. F2 — These RSUs were granted on August 6, 2025 (original grant 11,500; 638 post‑split) and vested on the first anniversary.
• No indication in the excerpt of a 10b5-1 plan or other trading plan.

Context

• This was a conversion/vesting event for RSUs. The matching disposal at $0.00 is consistent with shares being surrendered or withheld (commonly for tax withholding or settlement) rather than a market sale; the filing shows no sale proceeds.
• Such conversions and withholding actions are routine for equity compensation and do not by themselves signal a buy or sell decision by the insider.